These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 12860943)

  • 1. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
    Taplin ME; Rajeshkumar B; Halabi S; Werner CP; Woda BA; Picus J; Stadler W; Hayes DF; Kantoff PW; Vogelzang NJ; Small EJ;
    J Clin Oncol; 2003 Jul; 21(14):2673-8. PubMed ID: 12860943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.
    Suzuki H; Akakura K; Komiya A; Aida S; Akimoto S; Shimazaki J
    Prostate; 1996 Sep; 29(3):153-8. PubMed ID: 8827083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiandrogen withdrawal syndrome].
    Akimoto S
    Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
    Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
    Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
    J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor gene mutations in hormone-refractory prostate cancer.
    Wallén MJ; Linja M; Kaartinen K; Schleutker J; Visakorpi T
    J Pathol; 1999 Dec; 189(4):559-63. PubMed ID: 10629558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
    Taplin ME; Bubley GJ; Shuster TD; Frantz ME; Spooner AE; Ogata GK; Keer HN; Balk SP
    N Engl J Med; 1995 May; 332(21):1393-8. PubMed ID: 7723794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
    Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
    Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
    Tilley WD; Buchanan G; Hickey TE; Bentel JM
    Clin Cancer Res; 1996 Feb; 2(2):277-85. PubMed ID: 9816170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
    Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
    Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression.
    Salah Z; Maoz M; Cohen I; Pizov G; Pode D; Runge MS; Bar-Shavit R
    FASEB J; 2005 Jan; 19(1):62-72. PubMed ID: 15629896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.
    Gaddipati JP; McLeod DG; Heidenberg HB; Sesterhenn IA; Finger MJ; Moul JW; Srivastava S
    Cancer Res; 1994 Jun; 54(11):2861-4. PubMed ID: 8187068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
    Palmberg C; Koivisto P; Hyytinen E; Isola J; Visakorpi T; Kallioniemi OP; Tammela T
    Eur Urol; 1997; 31(2):216-9. PubMed ID: 9076469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
    Hsing AW; Gao YT; Wu G; Wang X; Deng J; Chen YL; Sesterhenn IA; Mostofi FK; Benichou J; Chang C
    Cancer Res; 2000 Sep; 60(18):5111-6. PubMed ID: 11016637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.